Modified-release hydrocortisone (Plenadren) launched for adrenal insufficiency

Plenadren (hydrocortisone) is indicated for maintenance therapy in adrenal insufficiency.

Modified-release hydrocortisone is not associated with the non-physiological cortisol peaks produced by standard glucocorticoid therapy.

Plenadren (hydrocortisone) is a modified-release hydrocortisone tablet given once daily. It is intended to better mimic the physiological pattern of cortisol production than standard glucocorticoid replacement therapy.

Cortisol exposure

In a randomised open-label 12-week crossover study in 64 patients with primary adrenal insufficiency, once-daily modified-release hydrocortisone resulted in increased cortisol exposure during the first four hours after intake in the morning, with reduced exposure in the late afternoon and evening and over the 24-hour period compared with standard-release hydrocortisone (given three times daily). The safety profile was similar to that of conventional hydrocortisone.

View Plenadren drug record
Further information: ViroPharma

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Back of man's head suffering from alopecia

Alopecia drug to be available on the NHS

In an NHS first, NICE is recommending ritlecitinib...

Stressed male GP with hand on head
Pseudoephedrine written

Pseudoephedrine prescribing information to highlight rare brain disorder risk

Safety information for pseudoephedrine products will...

New generics tracker

New generics - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest generic drugs...